- Conditions
- Liposarcoma, Leiomyosarcoma
- Interventions
- Yondelis, Dexamethasone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Aurora, Colorado • Coeur d'Alene, Idaho + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
- Drug · Combination Product · Other
- Lead sponsor
- Epkin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Santa Monica, California • Houston, Texas
- Conditions
- Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
- Interventions
- Sunitinib Malate (SU011248)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumor
- Interventions
- SA53-OS (phase 1), SA53-OS (phase 2)
- Drug
- Lead sponsor
- Lamassu Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Canton, Ohio • Cleveland, Ohio
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 651
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
- Interventions
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Sarcoma, Liposarcoma
- Interventions
- Palbociclib 200mg, Palbociclib 125mg
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sarcoma
- Interventions
- soblidotin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • New York, New York + 1 more
- Conditions
- Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Neoplasms
- Interventions
- GSK3901961, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
- Conditions
- Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma
- Interventions
- CMB305, atezolizumab
- Biological
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 18
- States / cities
- Palo Alto, California • Santa Monica, California • Aurora, Colorado + 15 more
- Conditions
- Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 10 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Park Ridge, Illinois + 6 more
- Conditions
- Liposarcoma, Dedifferentiated
- Interventions
- SPH4336
- Drug
- Lead sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 6 more
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Rhabdomyosarcoma, Dermatofibrosarcoma Protuberans, Endometrial Stromal Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
- Interventions
- saracatinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Rockledge, Pennsylvania
- Conditions
- Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Dedifferentiated Liposarcoma
- Interventions
- DCC-3014, Avelumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
- Interventions
- Dexrazoxane, Doxorubicin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
- Interventions
- Itacitinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma
- Interventions
- Durvalumab, Oleclumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leiomyosarcoma
- Interventions
- Ontorpacept (TTI-621), Doxorubicin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Santa Monica, California • Jacksonville, Florida • Tampa, Florida + 16 more